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1. Introduction 
The Bacillus Calmette-Guerin (BCG) is a live, attenuated vaccine 
from Mycobacterium bovis obtained by Albert Calmette and Camille 
Guerin through 230 in vitro passages between 1908 and 1921 when it 
was for the first time used in Paris. Since then BCG is 
distributed all over the word as preventive tool against 
tuberculosis (TB), although its use has changed over time owing to 
the different epidemiological conditions and despite the debate 
about its preventive effect reaching only 51% of risk reduction. 
Indeed, the BCG vaccination shows a positive protection on 
extrapulmonary TB and mortality in children but has a variable and 
only partial prevention against pulmonary disease in adults [1,2]. 
Alongside this current main use, other non-specific immunological 
effects of BCG have become evident over the years allowing its 
application in clinical management of several diseases (Fig.1). 
Since 1976, intravesical instillation of BCG represents the 
immunotherapy of bladder cancer [3] and to date it is an integral 
and approved part of the management of non-muscle invasive bladder 
cancer. Other neoplasms as colorectal cancer, lung cancer and 
melanoma, have been, especially in the past, the targets of BCG 
immunotherapy. Because of their immunologic background, a variety 
of diseases (asthma, diabetes type 1, multiple sclerosis, leprosy) 
have been evaluated for treatment with BCG [4].  
2. Immune mechanisms of BCG 
Although not fully clarified, the protective effect of BCG is 
warranted by a robust response of cellular immunity that occurs 
with the involvement of CD4+ T cells along with the Th-1 cytokines 
IFNγ, TNFɑ, and IL17 (Fig. 2). Subsequently, CD8+ T cells are also 
involved in the immunization process while IL-2 has a relevant 
role for central memory T cell responses [5].  
Similar mechanisms, even though with different biologic meanings, 
are evoked when antitumor immunity induced by BCG is required [6]. 
In this context, the local treatment of bladder cancer with BCG 
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instillations represents an interesting model, although not yet 
fully understood. Indeed, when the BCG is instilled in the bladder 
binds to fibronectin present at the endoluminal layer and forms 
fibronectin-BCG complexes embedded in both normal and tumor cells. 
The BCG antigens, expressed at the surface of urothelial, 
neoplastic and antigen-presenting cells, trigger an early, large, 
influx of neutrophils (75%) and macrophages then inducing a Th1 
response by CD4+ T cells with production of IFNγ, TNFβ, IL-2, and 
IL-12. Such a Th1 response finally activates the NK cells 
cytotoxic T lymphocytes (CTLs) that destroy the neoplastic cells. 
Moreover, a Th2 cytokine profile (IL-4, IL-5, IL-6, and IL-10) is 
produced but Th1 response seems to exert a more favorable 
antitumor action. Specific effects of some interleukins are the 
following: IL2 has a stimulatory effect on CTLs, IL18 activates 
CTLs and NK cells, and IL8, produced by activated macrophages, has 
a recruiting effect on PMN granulocytes. These latter provide the 
TNF-related apoptosis-inducing ligand (TRAIL) secretion, a member 
of TNF family that induces apoptosis in neoplastic but not in 
normal cells. To achieve an effective antitumor response a 
functional host immune system is a necessary prerequisite [7-9]; 
however, a limited number of cancer cells, a juxtaposition of BCG 
and tumor cells, and appropriate dose of BCG are also essential 
factors, all fulfilled in bladder cancer, for a effective action 
of immunotherapy [10]. 
The reactive arthritis (ReA) is an aseptic synovitis triggered by 
several pathogens either of the genitourinary or gastrointestinal 
tract and, among these, intravesical BCG should be included as 
recently reviewed [11]. Indeed, ReA may share many immunological 
mechanisms involved in intravesical BCG therapy. As first step, a 
CD4 T-cell response occurs at the site of inflammation, stimulated 
and maintained by bacterial components with the subsequent 
participation of CD8 T cells. However, the Th1 cytokine response 
(IFNγ, IL-2, IL-12) is unable to remove the triggering bacterial 
agent so a prevalence of Th2 response (IL-4 and IL10) is produced, 
keeping alive the bacteria in the joints. It is conceivable that 
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HLA-B27, often present in patients with ReA, may act as 
restriction molecule for antigenic bacterial peptides, presented 
to and cross recognized by cytotoxic CD8+ T lymphocytes, allowing 
the persistence of the inflammatory process even after the 
elimination of the bacteria [12]. The so-called molecular mimicry 
is the mechanism usually invoked to explain the autoimmune effects 
of infectious microorganisms; in the case of intravesical BCG, the 
shared homology between mycobacterial heat-shock protein HSP65 and 
cartilage proteoglycan link protein might be determining. Thus, 
the bacteria or bacterial antigens spreading from the bladder to 
the circulation may produce a systemic immune-mediated response 
having the joints as target, especially in the presence of genetic 
predisposition (positive HLA-B27 antigen) [13]. 
(Fig. 1. Here) 
3. Clinical applications of BCG  
3.1 Tuberculosis 
The specific, preventive anti-TB use, above mentioned, has 
revealed interesting non-specific effects of BCG vaccination 
because of its immunogenic action. One of these concomitant 
effects of BCG is a significant reduction in infant and child 
mortality attributable to causes other than TB. Since 1940 until 
the last ten years, several observations have focused on this 
effect in high-mortality countries; similarly, BCG immunization at 
birth reduce the death from respiratory infections and sepsis. 
Possibly, BCG immunization at birth favorably influences the 
antibody response to routine immunizations administered later in 
infancy (vaccinations against pneumococcal, Haemophilus influenzae 
type B, tetanus toxoid, and hepatitis B surface antigen)[4].  
3.2 Leprosy 
Leprosy is caused by infection with Mycobacterium leprae and the 
most common preventive strategy relies on BCG vaccination that 
was, at the beginning, widely used both for TB and leprosy [14]. 
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This latter shares the same protective immune mechanism with TB 
with increased production of Th-1 cytokines, i.e. IFNγ, TNFɑ, and 
IL17. The protective impact of BCG on leprosy is variable ranging 
from an overall protection of 41% to 76% for multibacillary and 
62% for paucibacillary forms, and with 41% for experimental trial, 
60% for observational studies, 53% for general population, and 68% 
for contact subjects. Despite this variability there is clear-cut 
evidence that BCG may exert a preventive effect against leprosy, 
mostly in population at higher risk as household contacts; 
although this effect declines with time, it persists over 30 years 
or more. Early diagnosis and multidrug therapy are the key-points 
of leprosy control, but BCG vaccine retains its important 
preventive role [15].  
Besides its definite role in the prevention of TB and leprosy, BCG 
vaccination has been employed in other clinical conditions given 
the above mentioned non-specific effects.  
3.3 Asthma and other hypersensitivity diseases 
The BCG has a stimulatory effect on Th1 cytokines while inhibits 
the Th2 immunologic response and consequently it counteracts the 
risk of Th2-dependent atopic diseases [16]. Based on this 
hypothesis an epidemiological association between BCG vaccination 
in early life, asthma and other atopic conditions has been 
evaluated with conflicting results. Some recent meta-analyses 
failed to prove a significant protective effect of BCG against 
allergy in general, atopic dermatitis or eczema, allergic 
rhinoconjunctivitis, urticaria, and food allergy, while it might 
provide some benefits against asthma [17,18]. However, other 
studies did not confirm the suggested protective role of BCG 
vaccination on asthma and/or other allergic conditions [19].  
3.4 Type 1 diabetes 
Type 1 diabetes results in part from impaired activation of 
transcription factor NF-kB in a subpopulation of activated T-
cells, which become more sensitive to TNFɑ-induced apoptosis. The 
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cytokine TNFɑ selectively kills autoreactive T-cells, namely the 
only disease-causing cells, allowing pancreas regeneration. The 
ability of BCG to stimulate the production of TNFɑ, with similar 
results to those obtained with TNFɑ administration, has supported 
its use as possible treatment of diabetes type 1 [20].  
In the past immunotherapy with single, low dose of BCG in patients 
with late-stage pre-diabetes was proved to induce a clinical 
remission in some patients [21], but these results were not 
confirmed in newly diagnosed diabetic children evaluated for 18 
[22] and 24 months after vaccination [23]. However, in a recent 
controlled trial two low-dose BCG vaccinations in patients with 
long-term type 1 diabetes resulted in a rapid release of dead 
insulin-autoreactive T cells, as consequence of TNFɑ activity, and 
in a significant increase in C-peptide secretion, as expression of 
a restored beta-cell function. Interestingly, similar results were 
documented in a placebo patient with unexpected EBV infection, a 
well-known trigger of innate immunity by inducing a host TNFɑ 
response [24]. 
3.5 Multiple sclerosis 
Multiple sclerosis (MS) is a neurological autoimmune disorder 
whose specific mechanisms remain to be fully elucidated [25]. The 
rationale for the use of BCG in MS rests on the documented 
suppression of autoimmune responses in experimental autoimmune 
encephalomyelitis, an animal model of human MS [26]. Among the 
complex immune-mediated processes responsible for MS a conflicting 
meaning seems to concern clinical results of anti-TNFɑ treatments 
as well as the biology of TNFɑ. This cytokine is abnormally 
increased in the cerebrospinal fluid and in active lesions of 
patients with MS, but TNFɑ-agonists may worse MS and induce 
demyelinating syndromes in other autoimmune diseases. This 
apparent paradoxical effect may be explained by the presence of a 
single nucleotide polymorphism (rs1800693) in the TNFRSF1A gene, 
which encodes tumor necrosis factor receptor 1 (TNFR1), associated 
with MS, but not with other autoimmune diseases. The MS risk 
 7
allele directs expression of a new, soluble form of TNFR1, a MS-
associated TNFR1 variant,that can block TNF mimicking the effect 
of TNFɑ-antagonists in rheumatoid arthritis, psoriasis, and 
Crohn’s disease [27]. 
A trial with BCG vaccine in MS has shown evidence of reduced 
disease activity in a period of 6 months in 14 patients with 
relapsing-remitting MS [28]. There was a consistent and 
significant reduction (57%) in the mean number of active MRI 
lesions from the run-in period to the post- BCG period without 
serious side effects. 
3.6 Cancer 
The observation that patients with TB were less frequently 
affected by cancer led to evaluate the effect of live, attenuated 
BCG as adjuvant immunotherapy (mostly with autologous tumor cells) 
for a variety of neoplasms as colorectal cancer, lung cancer, 
melanoma, and renal cell carcinoma. The underlying hypothesis is 
that increasing the immunogenicity of tumor cells with adjuvants 
will enhance immune responses to the endogenous tumor antigens. 
The prerequisite for a positive outcome was a limited tumor 
expansion. However, because of the lack of documented efficacy in 
several studies such an use was gradually abandoned also for the 
more concrete prospective of novel and specific vaccines. Indeed, 
the molecular definition of cancer-associated antigens introduced 
the possibility of specific vaccines and a new era in genetically 
engineered whole-cell vaccination has involved the modification of 
tumor cells through transfer of genes encoding cell membrane 
immunostimulatory molecules or cytokines. 
To date BCG is the most common intravesical therapy for treating 
non-muscle-invasive urothelial carcinoma and it is able to reduce 
the recurrence rate and the risk of progression to muscle-invasive 
disease in patients with carcinoma in situ (gold standard 
therapy), as well as superficial bladder tumors [8]. The 
immunologic mechanisms of BCG therapy have been already referred; 
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it is interesting to note that the local immunogenic action of 
intravesical BCG is much more powerful if compared with systemic 
effect of intradermal route in other malignancies. Intravesical 
BCG is commonly administered once weekly for 6 weeks as induction 
following transurethral resection of the bladder tumor. The 
optimal maintenance schedules are to be determined but mostly 
include three weekly instillations at 3 month intervals for 3 
years although reduced doses and duration has been recently 
proposed [29].  
4. Autoimmune phenomena from BCG  
As with any vaccine, BCG also can be described as a "double-acting 
tool" because its own immunogenicity produces on one side a 
preventive effect in a variety of diseases and on the other side 
it may trigger a number of autoimmune phenomena.  
Although several immune-mediated adverse events triggered by the 
BCG vaccination have been reported thus far, a clear causal link 
has not been demonstrated. Furthermore some cases might be 
correlated to other environmental factors or represent normal 
responses to foreign proteins. Conceptually, an immune-mediated 
response against self could results from host response to any 
component of the vaccine [30]. In presence of genetic and 
environmental factors the host immune response may be triggered by 
various mechanisms mainly through non-specific B-lymphocyte 
stimulation with polyclonal B-cell expansion, idiotypic cross-
reaction, and molecular mimicry (Fig. 2). 
BCG vaccination for TB is a safe and well-tolerated with very low 
rate of side effects, ranging from local reactions to disseminated 
BCG disease, with various degree of severity, and mostly of 
infectious nature. To a large extent the more serious 
complications occur in immunocompromised subjects, as in HIV-
infected infants. Equally rare, although speculatively more 
intriguing, are the post-vaccine autoimmune phenomena that, 
however, have different clinical significance according to the 
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route of administration (systemic-intradermal or local-
intravesical).  
(Fig. 2. Here) 
4.1 Intradermal BCG  
4.1.1 Arthritis 
Arthritis following cancer immunotherapy has been described in 10 
of 159 patients treated for various types of malignancy. The main 
clinical pattern was a bilateral and symmetric polyarthritis, 
which was predominantly confined to small joints of the hands, 
preceded by morning stiffness, and associated with elevated 
inflammatory markers; it occurred within 1 to 5 months from first 
BCG injection and it was exacerbated by subsequent BCG injection. 
The arthritis partially recovered in 1-3 months with non-steroid 
anti-inflammatory drugs treatment. Synovial fluid analysis and 
biopsy, when done, were negative for acid-fast bacilli and 
indicative of nonspecific chronic inflammation [31]. An acute 
inflammatory polyarthritis with skin maculopapular rash was 
reported in an healthy woman following intradermal BCG. The 
culture of synovial fluid was repeatedly negative; after failure 
of antibiotic multi-therapy the clinical symptoms promptly and 
fully subsided with corticosteroid treatment [32] 
4.1.2 Dermatomyositis  
This autoimmune condition is rarely reported as a consequence of 
BCG vaccination. Two cases (one after re-vaccination) have been 
diagnosed by skin and muscle biopsy [33]. Generally, a substantial 
increase in the incidence of dermatomyositis or polymyositis after 
any kind of vaccine has not been reported. 
4.1.3 Takayasu’s arteritis (TA) 
Based on historical, epidemiological and immunologic background a 
link between Takayasu’s arteritis and TB/BCG has been proposed in 
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the past [34]. Indeed, both diseases present a granulomatous 
histological feature; patients with TA produce both humoral and 
cell-mediated responses against antigens of M. tuberculosis and 
have an higher reactivity of peripheral lymphocytes to HSP 65 kDa 
heat-shock protein that is remarkably induced in the media and the 
vasa vasorum of TA biopsies. However, this intriguing linkage has 
been poorly studied and, at present, not confirmed [35]. 
4.1.4 Kawasaki’s disease (KD) 
A reaction at the BCG inoculation site (erythema, induration or 
crust formation) is common, especially in Japan, and it is present 
in about 30–50% of KD patients. Although this sign is more 
frequent than cervical lymphadenopathy in children with complete 
KD aged 3–20 months, it is not included among diagnostic criteria. 
The skin reaction appears early (24–48 hours) after febrile onset 
and is replaced by a crust immediately after the fever subsides. 
It is considered an important toll for early diagnosis in febrile 
children, especially in those younger than 2 years. It has been 
hypothesized that cross-reactivity may occur between specific 
epitopes of mycobacterial 65-kDa heat-shock protein and the human 
homologue, heat-shock protein 65 [36]. 
4.1.5 Miscellaneous adverse events 
Several pathological conditions are associated with BCG 
vaccination, usually as anecdotal reports. Immediate 
hypersensitivity reactions are associated with sensitization to 
dextran; moreover, delayed reactions as maculopapular exanthems, 
erythema nodosum, urticarial vasculitis, and neutrophilic 
dermatoses (Sweet’s syndrome and pyoderma gangrenosum) rarely 
occur [37]. Cutaneous sarcoidosis [38], psoriasis skin lesions 
[39], guttate psoriasis-like lesions [40], and an extensive 
ulcerating vasculitis, defined as granulomatous-type one (type IV 
hypersensitivity reaction) [41] have been reported after BCG 
vaccination. A special mention must be reserved to the 
relationship of BCG with MS, a disease in which the specific 
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immunization might be protective (see above) or inductive. In our 
knowledge, a causal link between BCG vaccination and MS is 
referred in only one case [42], while reports of MS following 
vaccine against hepatitis B virus are much more frequent [43]. 
Moreover, no significantly increased risk of developing MS after 
vaccination for BCG was found in a recent review [44]. In the 
past, cases of polyneuropathy after BCG vaccination or re-
vaccination have been occasionally reported [45,46]. 
 
4.2 Intravesical BCG  
Side effects from intravesical BCG are rare since they are 
documented in less than 5% of cases and generally classified as 
local and systemic, both infective, or secondary to 
hypersensitivity response. Because they mainly occur after 
systemic absorption of the vaccine a correct administration is 
mandatory following the absolute contraindications [47]. The 
analysis of the septic adverse events, either local or systemic, 
is not the purpose of this survey, which is focused on the 
autoimmune reactions induced by BCG; therefore, objective 
limitations are encountered to correctly review the literature, 
especially when the data are from urologic source. For instance, 
often articular symptoms are simply referred as “arthralgia” or 
“arthritis” without any detail and are associated to an 
unspecified “skin rash” and defined as “possible allergic 
reactions”. Similarly, side effects as granulomatous pneumonia or 
hepatitis are reported without sufficient data to support the 
possible link with intravesical BCG and the autoimmune mechanism. 
In such cases it may be really difficult to clearly establish 
whether they represent an infectious complication or a 
hypersensitivity reaction to BCG. Indeed, histological and 
cultural findings from affected organs are often unable to 
demonstrate the presence of acid-fast bacilli. In this contest, 
however, some interesting data arise to our attention. 
4.2.1 Arthritis and other rheumatic diseases 
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An inflammatory involvement of joints is a well-known side effect 
of intravesical BCG, reported with a variable frequency, ranging 
from 0.5% to 28.1% according to various series [11]. Its clinical 
pattern is a polyarthritis comparable to arthritis triggered by 
other agents and generally characterized by typical clinical 
features of classical reactive arthritis (ReA). Also intravesical 
BCG-related ReA is characterized by the evidence of preceding 
infection with a known trigger bacterium of manifest source site, 
the articular inflammation is aseptic, and it invariably shows 
latency from the antigen exposure. By far, alone or in 
association, the large joints of lower limbs are the most involved 
and the asymmetry is the prevalent pattern. Inflammatory low back 
pain, albeit non-frequently, is also reported. As part of the 
musculoskeletal complaints, enthesitis, tendinitis, bursitis and 
dactylitis are typically present even though never as unique 
reactive feature. Fever is the most common associated symptom 
followed by typical hypersensitivity symptoms such as 
conjunctivitis, urethritis, uveitis, balanitis, and ketatoderma. A 
definite genetic link is documented by HLA B27 carriers in about 
half cases, supporting the concept that, when MHC class I 
associations occur, the failure of immunological tolerance in 
combination with environmental factors, such as a microbial agent 
in the bladder, can lead to immune-mediated inflammatory reaction 
in the joints. NSAIDs and/or corticosteroids are the mainstay of 
pharmacologic treatment, that is largely effective, and arthritis 
usually has a benign course with poor tendency to chronicity [11].  
It is worth noting the comparison with polyarthritis secondary to 
immunotherapy with intradermal BCG (31,32) reported only in few 
cases; their different articular phenotypes might be correlated to 
the distinct routes of administration with quite different 
immunogenic action. 
Other anecdotal autoimmune rheumatic diseases following 
intravesical BCG have been reported. In particular, Sjögren's-like 
syndrome, confirmed by salivary gland scintigraphy and biopsy of 
the submandibular gland showing a lymphoplasmacytoid sialoadenitis 
 13
without granuloma [48], polymyalgia rheumatica with temporal 
artheritis [49], remitting seronegative symmetrical synovitis 
pitting oedema [50], and cryoglobulinemic vasculitis [51]. 
4.2.2 Organ-specific hypersensitivity reactions 
Provided that the lack of any microbiological evidence of BCG 
dissemination does not exclude an infection with M. tuberculosis 
or mycobacteria other than M. bovis, several reports of non-
infective organ involvement may indicate an underlying 
hypersensitivity mechanism. Similar cases were also referred from 
intradermal BCG immunotherapy for neoplasms other than bladder 
cancer since viable mycobacteria had not been detected in the 
lesions. Pneumonitis/hepatitis were reported with a prevalence of 
0.7% in a series of 2,602 patients treated intravesical BCG for 
superficial bladder cancer but were ascribed to systemic BCG 
infection [52]. Although it is debated whether these events are 
really due to a sterile hypersensitivity reaction, the lacking 
evidence of infection by acid-fast bacilli and the prompt response 
to steroid treatment (alone or added to anti-tubercular drugs), 
support this hypothesis. Pneumonitis is generally described as 
interstitial and bilateral with a radiological appearance of 
ground glass opacites and multiple pulmonary nodules, expression 
of non-caseating sterile granulomas [53-57]. Moreover, 
granulomatous (non-caseating epithelioid granulomas with Langhans 
giant cells) hepatitis may be concurrently associated with lung 
involvement. Cultures, PCR analysis and Ziehl-Neelsen staining 
performed in blood, bone marrow, urine, feces, biopsy samples, and 
broncho-alveolar lavage failed to isolate Mycobacterium species. 
[58-60]. A granulomatous, sterile hepatitis is also described as 
single complication of intravesical BCG, although much more rarely 
than infectious one [61]. Even the kidney may be the target of 
hypersensitivity reaction to intravesical BCG, which may induce an 
interstitial nephritis with non-necrotizing, sterile granulomas 
responsive to steroid therapy [62,63]. Anecdotally, renal 
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involvement may be observed in association with pneumonitis and 
hepatitis in the same patient [64]. In these cases corticosteroid 
therapy was always effective either as monotherapy or second line 
treatment after the failure of anti-tubercular drugs. 
An interesting report suggested a possible involvement of both 
pathogenetic mechanisms, namely infection and hypersensitivity, in 
the same patient with multi-organ involvement and a significant 
time course. Firstly, granulomatous hepatitis with positive PCR 
for mycobacterial DNA and aortic valve vegetations occurred after 
intravesical BCG; these manifestations were successfully treated 
with 3-drug anti-tubercular therapy. Several days after, cutaneous 
leucocytoclastic vasculitis, leucopenia, thrombocytopenia, 
antinuclear antibodies, and rheumatoid factor appeared together 
with a persistent impaired cholestasis. For a possible hepatotoxic 
effect, ethambutol and rifampin were stopped while ofloxacine was 
added to isoniazid. Three months later, the granulomatous lesions 
were spread to lungs (interstitial micronodular pattern on chest 
CT), spleen (multiple foci on abdominal ultrasound), bone marrow, 
and liver (extensive no caseating granulomata at liver biopsy, 
with negative stains and cultures for acid-fast bacilli). In 
addition, marked hypercalcemia was documented for the first time. 
Therefore, corticosteroid therapy was given with complete recovery 
of the systemic features after 15-month follow-up. The Authors 
suggested both an early infective phase (PCR positive and response 
to anti-TB treatment), probably triggered by too short time 
interval between surgery and intravesical BCG, and a late, 
hypersensitivity reaction (vasculitis, cytopenias, antinuclear 
antibodies, and rheumatoid factor seropositivity) with 
disseminated, sterile granulomatosis, responsible for 
hypercalcemia due to activation of reticuloendothelial system as 
in sarcoidosis. Concordantly with their pathogenetic hypothesis, 
this second phase of disease showed a marked response to low-dose 
corticosteroid therapy [65]. 
4.2.3 Skin 
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Not otherwise specified “rash” are reported in 0,3% of patients 
[52]; however, cutaneous complications of intravesical BCG have 
been seldom described in anecdotal observations [11]. Id reaction 
or auto-eczematization (a dermatitis appearing at a distance from 
an initial site of infection or sensitization) was referred in a 
patient as an intensely pruritic, scaly, erythematous eruption 
involving all extremities 2 weeks after starting weekly 
intravesical use of BCG therapy. The skin biopsy showed spongiotic 
dermatitis with overlying scaling and an eosinophilic infiltrate. 
The eruption resolved with topical corticosteroids [66]. Finally, 
vitiligo has been also reported as autoimmune side-effect of 
intravesical BCG [67]. 
4.2.4 Ophthalmopathy  
Uveitis can be caused by intraocular infections or as a result of 
autoimmune stimulation. Several reports, also after BCG 
vaccination, focused on ocular complications of intravesical BCG 
but not infrequently a clear-cut exclusion of infective origin is 
lacking, probably due to low sensitivity of diagnostic tools. 
However, some cases show a complete recovery with topical or oral 
steroid therapy. Of interest, when searched, HLA B27 was negative 
[68-70], contrarily to that observed in patients with uveitis and 
reactive arthritis (7.7%), invariably HLA B27-positive [11]. An 
autoimmune retinopathy associated with intravesical BCG therapy 
has been also reported [71]. 
 
4.2.5 Others  
Among the very rare reports may be worthy to note one case of 
anaphylactoid purpura in the lower legs and another case of 
Henoch-Schönlein purpura occurring after intravesical BCG therapy 
in the absence of any concomitant possible cause, [72,73].  
 
5. BCG vaccination in autoimmune diseases  
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In spite of the global tuberculosis control achieved in Central 
Europe, the disease represents currently one of the major health 
problems, particularly in development countries, high-income 
countries, Latin America, and the Western Pacific region [74]. 
Although with variable efficacy and largely ineffective on the 
most common lung infection, the BCG vaccination remains the only 
currently licensed TB vaccine. In this context, the relationship 
between BCG vaccination and autoimmune diseases is another not 
negligible aspect. In fact, the risk of getting TB, the protective 
effect of BCG and the possible harms of vaccination are, as for 
any vaccine, the main issues to take in account in patients with 
systemic autoimmune disorders. The inherent risk of the single 
disease, the geographic risk for TB and the use of 
immunosuppressive therapy in rheumatic diseases are all factors 
that create a new scenario. In patients with rheumatoid arthritis 
corticosteroids, disease-modifying drugs and, especially, TNFα 
blocking agents are associated with increased risk of TB although 
reduced by the screening procedures for latent TB. In ankylosing 
spondylitis patients treated with infliximab, etanercept, and 
adalimumab no cases of active TB has been reported [75]. The BCG 
vaccination in patients with autoimmune rheumatic diseases has 
been recently evaluated in the EULAR evidence-based review where 
it is stated that BCG vaccination is not recommended in patients 
with auto-immune inflammatory rheumatic diseases. This advice 
relies upon the following considerations: the incidence of active 
TB is increased in patients with autoimmune rheumatic diseases 
especially when are treated with immunosuppressive drugs (mainly 
TNFα blocking agents), these cases are mostly reactivations on 
latent TB that could not be prevented by the vaccine, the 
protective effect of BCG vaccination in adults is not clearly 
demonstrated, BCG vaccine carries attenuated, live, mycobacteria 
that, in immunocompromised patients might increase the risk of 
disseminated TB [76]. However, some exceptions should be evaluated 
as the case of health care workers exposed to resistant TB [77].  
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Legend to the Figures. 
 
Figure. 1. Clinical applications of BCG. Apart from its current 
use in the vaccination against tuberculosis and leprosy, BCG has 
been proposed as a possible immunotherapy treatment in both 
neoplastic and autoimmune diseases. 
 
Figure. 2.Summary of the main pathogenetic mechanisms correlated 
with BCG vaccination or intravescical BCG immunotherapy for 
bladder cancer, as well as the possible BCG-driven autoimmune 
disorders.  
* cross-reaction between BCG heat-shock protein HSP65 and 
cartilage proteoglycan link protein represents one example of 
possible molecular mimicry pathogenetic mechanism. 
 
